Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

• Main Authors: Sai-Qi Wang (Author), Qiu-Xu Teng (Author), Shuai Wang (Author), Zi-Ning Lei (Author), Hui-Hui Hu (Author), Hui-Fang Lv (Author), Bei-Bei Chen (Author), Jian-Zheng Wang (Author), Xiao-Jing Shi (Author), Wei-Feng Xu (Author), Hong-Min Liu (Author), Xiao-Bing Chen (Author), Zhe-Sheng Chen (Author), Bin Yu (Author)
• Format: Book
• Published: Elsevier, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Multidrug resistance (MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein (P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies of the triazolo[1,5-a]pyrimidine-based compound WS-71...